Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Silence Therapeutics, retaining the price target of $75.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Patrick Trucchio has given his Buy rating due to a combination of factors including the clinical advancements and strategic pipeline prioritization of Silence Therapeutics. The company’s recent progress with its siRNA therapies, divesiran and zerlasiran, has been promising. Divesiran has shown best-in-class potential in treating polycythemia vera, with Phase 1 data indicating durable hematocrit control and a reduction in the need for phlebotomies, alongside a favorable safety profile. The Phase 2 SANRECO trial is progressing well, with over half of the enrollment completed and expected to finish by the end of 2025.
Meanwhile, zerlasiran is poised for a rapid initiation of a cardiovascular outcomes trial, supported by strong regulatory and expert backing. The company’s strategic focus on high-value programs, coupled with a solid cash runway extending into 2028, positions it well for sustained value creation. Upcoming clinical milestones, potential partnerships, and advancements in their delivery platform are expected to drive significant upside, supporting the Buy rating and the $75 price target.